Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 2052-2060

  Hirata, Tomomi ^a,b   Zheng, Qingfeng ^a,c   Chen, Zhao ^a,d   Kinoshita, Hiroyasu ^a,b   Okamoto, Junichi ^a,b   Kratz, Johannes ^a   Li, Hui ^a   Lui, Natalie ^a   Do, Hanh ^a   Cheng, Tiffany ^a   Tseng, Hsin Hui Katty ^a   Koizumi, Kiyoshi ^b   Shimizu, Kazuo ^b   Zhou, Hai Meng ^d   Jablons, David ^a,e   He, Biao ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c Department of Biochemistry and Molecular BiologyCancer Hospital of Peking University   (China)

^d TSINGHUA UNIVERSITY   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Marker; Mesothelioma

Indexed keywords

TUMOR MARKER; WNT7A PROTEIN; WNT PROTEIN; WNT7A PROTEIN, HUMAN;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SMOKING; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; WNT PROTEINS;

EID: 84924891714     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3771     Document Type: Article

References (42)

1. Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005.
2. Musk AW and de Klerk NH: Epidemiology of malignant mesothelioma in Australia. Lung Cancer 45: S21-S23, 2004.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003.
4. Borasio P, Berruti A, Bille A, et al: Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 33: 307-313, 2008.
5. Flores RM, Zakowski M, Venkatraman E, et al: Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2: 957-965, 2007.
6. Krug LM, Pass HI, Rusch VW, et al: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27: 3007-3013, 2009.
7. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y and Vogelzang NJ: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723-731, 1998.
8. Neumann V, Rutten A, Scharmach M, Muller KM and Fischer M: Factors influencing long-term survival in mesothelioma patientsresults of the German mesothelioma register. Int Arch Occup Environ Health 77: 191-199, 2004.
9. Metintas M, Metintas S, Ucgun I, et al: Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med 95: 829-835, 2001.
10. Baas P: Predictive and prognostic factors in malignant pleural mesothelioma. Curr Opin Oncol 15: 127-130, 2003.
11. Kumar-Singh S, Jacobs W, Dhaene K, et al: Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186: 300-305, 1998.
12. Edwards JG, Swinson DE, Jones JL, Waller DA and O'Byrne KJ: EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54: 399-407, 2006.
13. Edwards JG, Faux SP, Plummer SM, et al: Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 8: 1857-1862, 2002.
14. Lopez-Rios F, Chuai S, Flores R, et al: Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66: 2970-2979, 2006.
15. Gordon GJ, Rockwell GN, Godfrey PA, et al: Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11: 4406-4414, 2005.
16. Shimizu E, Coxon A, Otterson GA, et al: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9: 2441-2448, 1994.
17. Modi S, Kubo A, Oie H, Coxon AB, Rehmatulla A and Kaye FJ: Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene 19: 4632-4639, 2000.
18. Giacinti C and Giordano A: RB and cell cycle progression. Oncogene 25: 5220-5227, 2006.
19. Cote RJ, Jhanwar SC, Novick S and Pellicer A: Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 51: 5410-5416, 1991.
20. Wong L, Zhou J, Anderson D and Kratzke RA: Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 38: 131-136, 2002.
21. Yang CT, You L, Yeh CC, et al: Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 92: 636-641, 2000.
22. Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810, 2004.
23. Boersma CJ, Bloemen M, Hendriks JM, van Berkel EA, Olijve W and van Zoelen EJ: Homeobox proteins as signal transduction intermediates in regulation of NCAM expression by recombinant human bone morphogenetic protein-2 in osteoblast-like cells. Mol Cell Biol Res Commun 1: 117-124, 1999.
24. Ohira T, Gemmill RM, Ferguson K, et al: WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 100: 10429-10434, 2003.
25. Riddle RD, Ensini M, Nelson C, Tsuchida T, Jessell TM and Tabin C: Induction of the LIM homeobox gene Lmx1 by WNT7a establishes dorsoventral pattern in the vertebrate limb. Cell 83: 631-640, 1995.
26. Timmreck LS, Pan HA, Reindollar RH and Gray MR: WNT7A mutations in patients with Mullerian duct abnormalities. J Pediatr Adolesc Gynecol 16: 217-221, 2003.
27. Bui TD, Lako M, Lejeune S, et al: Isolation of a full-length human WNT7A gene implicated in limb development and cell transformation, and mapping to chromosome 3p25. Gene 189: 25-29, 1997.
28. Kirikoshi H and Katoh M: Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int J Oncol 21: 895-900, 2002.
29. Raz DJ, Ray MR, Kim JY, et al: A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 14: 5565-5570, 2008.
30. Fennell DA, Parmar A, Shamash J, et al: Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23: 184-189, 2005.
31. Miller C, Degenhardt K and Sassoon DA: Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis. Nat Genet 20: 228-230, 1998.
32. Mericskay M, Kitajewski J and Sassoon D: Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development 131: 2061-2072, 2004.
33. Parr BA and McMahon AP: Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a. Nature 395: 707-710, 1998.
34. Li S, Chiang TC, Davis GR, Williams RM, Wilson VP and McLachlan JA: Decreased expression of Wnt7a mRNA is inversely associated with the expression of estrogen receptoralpha in human uterine leiomyoma. J Clin Endocrinol Metab 86: 454-457, 2001.
35. Pinton G, Brunelli E, Murer B, et al: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 69: 4598-4604, 2009.
36. Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2: 777-785, 2002.
37. Andujar P, Wang J, Descatha A, et al: p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer 67: 23-30, 2010.
38. Becklake MR, Thomas D, Liddell F and McDonald JC: Follow-up respiratory measurements in Quebec chrysotile asbestos miners and millers. Scand J Work Environ Health 8: 105-110, 1982.
39. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
40. Flores EM: Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 49: S71-S74, 2005.
41. Tsao AS, Mehran R and Roth JA: Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer 10: 36-41, 2009.
42. Weder W, Kestenholz P, Taverna C, et al: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22: 3451-3457, 2004.